Valuation: Zai Lab Limited

Market Cap 2.05B 1.78B 1.66B 1.52B 2.88B 196B 2.92B 19.52B 7.66B 97.52B 7.71B 7.54B 323B P/E 2026 *
-8.14x
P/E 2027 * -9.72x
Enterprise Value 1.56B 1.35B 1.26B 1.16B 2.19B 149B 2.22B 14.83B 5.82B 74.08B 5.86B 5.73B 245B EV / Sales 2026 *
3.48x
EV / Sales 2027 * 2.83x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 day+1.96%
1 week-6.02%
1 month-1.27%
3 months-11.86%
6 months+12.23%
Current year+6.85%
1 week 15.3
Extreme 15.3
16.3
1 month 15.3
Extreme 15.3
17.8
Current year 13.2
Extreme 13.2
21
1 year 13.2
Extreme 13.2
34
3 years 12.4
Extreme 12.4
38.2
5 years 12.4
Extreme 12.4
130
10 years 12.4
Extreme 12.4
162
Manager TitleAgeSince
Chief Executive Officer 61 2014-03-31
Director of Finance/CFO 58 2023-07-06
President 62 2022-11-30
Director TitleAgeSince
Chairman 61 2014-03-31
Director/Board Member 83 2016-12-31
Director/Board Member 75 2016-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%-6.02% - - 2.05B
+3.29%+16.25%+39.81%+2.79% 76.15B
-2.75%+48.50%+48.50%+48.50% 47.83B
+2.72%-9.39%+17.04%+176.83% 48.89B
-3.81%+7.74%-54.57%-54.17% 41.37B
-2.40%+0.38%+58.55%-24.89% 29.99B
-2.82%+1.57%+59.59%+87.57% 24.23B
-5.35%+1.39%+85.45%-53.41% 21.75B
-1.59%-3.61%-11.53%+150.58% 19.25B
-0.42%+2.89%+74.55%+128.45% 17.14B
Average -1.12%+1.48%+35.27%+51.36% 36.29B
Weighted average by Cap. -0.60%+2.98%+30.74%+43.63%

Financials

2026 *2027 *
Net sales 448M 388M 361M 332M 627M 42.7B 638M 4.26B 1.67B 21.27B 1.68B 1.64B 70.46B 595M 516M 480M 441M 833M 56.72B 847M 5.65B 2.22B 28.25B 2.23B 2.18B 93.59B
Net income -244M -212M -197M -181M -342M -23.29B -348M -2.32B -912M -11.6B -917M -897M -38.43B -159M -138M -128M -118M -223M -15.15B -226M -1.51B -593M -7.55B -597M -583M -25B
Net Debt -493M -428M -398M -366M -692M -47.07B -703M -4.69B -1.84B -23.44B -1.85B -1.81B -77.68B -371M -322M -300M -276M -521M -35.43B -529M -3.53B -1.39B -17.64B -1.39B -1.36B -58.46B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Date Price Change
26-07-31 €15.60 +1.96%
26-07-30 €15.30 -3.16%
26-07-29 €15.80 -1.25%
26-07-28 €16.00 -1.84%
26-07-27 €16.30 -1.81%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
18.27USD
Average target price
33.30USD
Spread / Average Target
+82.28%

Quarterly revenue - Rate of surprise